Welcome to our dedicated page for Tarsus Pharmaceuticals news (Ticker: TARS), a resource for investors and traders seeking the latest updates and insights on Tarsus Pharmaceuticals stock.
Tarsus Pharmaceuticals, Inc. reports developments tied to its commercial eye-care franchise and biopharmaceutical pipeline. Company news commonly covers XDEMVY, its lotilaner ophthalmic solution marketed in the U.S. for Demodex blepharitis, including product-sales updates, prescribing trends, conference presentations, and international regulatory milestones for TP-03 through its Greater China partner.
Updates also address pipeline programs such as TP-04 for ocular rosacea and TP-05, an investigational oral lotilaner tablet being studied for Lyme disease prevention. Recurring corporate items include quarterly and annual financial results, investor-conference participation, board and governance changes, and business updates related to Tarsus' ophthalmology-focused commercialization strategy.
Tarsus Pharmaceuticals, a late-stage biopharmaceutical company, has successfully completed its initial public offering, closing the sale of 6,325,000 shares at $16.00 each, raising approximately $101.2 million. The offering included 825,000 shares from the underwriters' additional option. Shares began trading on the Nasdaq Global Select Market under the ticker 'TARS' on October 16, 2020. Tarsus focuses on developing therapies for unmet needs in ophthalmology and other areas, with its lead candidate TP-03 in Phase 2b/3 trials for Demodex blepharitis.
Tarsus Pharmaceuticals has priced its initial public offering at $16.00 per share, aiming to raise approximately $88.0 million before expenses. The offering includes 5,500,000 shares, with an additional option for underwriters to purchase 825,000 shares. Trading of Tarsus’ common stock is set to commence on the Nasdaq Global Select Market under the symbol 'TARS' on October 16, 2020. The offering is anticipated to close around October 20, 2020, following standard closing conditions.